LFWD
Lifeward Ltd.
Medical - Devices
Market Cap$10M
5Y Perf.-93.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LFWD vs MBOT
Revenue, margins, valuation, and 5-year total return — side by side.
MBOT
Microbot Medical Inc.
Medical - Instruments & Supplies
Market Cap$143M
5Y Perf.-71.8%
LFWD vs MBOT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LFWD | MBOT |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $10M | $143M |
| Revenue (TTM) | $22M | $0.00 |
| Net Income (TTM) | $-20M | $-13M |
| Gross Margin | 38.3% | — |
| Operating Margin | -76.7% | — |
| Total Debt | $2M | $111K |
| Cash & Equiv. | $2M | $3M |
LFWD vs MBOT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LFWD
MBOT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lifeward Ltd. (LFWD) | 100 | 6.1 | -93.9% |
| Microbot Medical In… (MBOT) | 100 | 28.2 | -71.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LFWD vs MBOT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBOT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Lifeward Ltd. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LFWD
Lifeward Ltd.
The Income Pick
LFWD is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.22
- Rev growth -14.1%, EPS growth 57.1%, 3Y rev CAGR 58.7%
- Lower volatility, beta 1.22, Low D/E 18.8%, current ratio 1.31x
Best for: income & stability and growth exposure
MBOT
Microbot Medical Inc.
The Long-Run Compounder
MBOT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -99.4% 10Y total return vs LFWD's -100.0%
- 3.0% margin vs LFWD's -90.4%
- -16.8% vs LFWD's -60.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LFWD | -14.1% revenue growth vs MBOT's -17.1% |
| Quality / Margins | MBOT | 3.0% margin vs LFWD's -90.4% |
| Stability / Safety | LFWD | Beta 1.22 vs MBOT's 1.90 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MBOT | -16.8% vs LFWD's -60.4% |
| Efficiency (ROA) | MBOT | -34.4% ROA vs LFWD's -78.4%, ROIC -6.2% vs -122.9% |
LFWD vs MBOT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
LFWD vs MBOT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMBOTLAGGINGLFWD
LFWDLifeward Ltd.
1leads
MBOTMicrobot Medical Inc.
2leads
6 Total Categories
CATEGORYLEADERvs LFWDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LFWD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MBOT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MBOT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LFWD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LFWD and MBOT operate at a comparable scale, with $22M and $0 in trailing revenue.
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| RevenueTrailing 12 months | $22M | $0 |
| EBITDAEarnings before interest/tax | -$17M | -$14M |
| Net IncomeAfter-tax profit | -$20M | -$13M |
| Free Cash FlowCash after capex | -$17M | -$11M |
| Gross MarginGross profit ÷ Revenue | +38.3% | — |
| Operating MarginEBIT ÷ Revenue | -76.7% | — |
| Net MarginNet income ÷ Revenue | -90.4% | — |
| FCF MarginFCF ÷ Revenue | -76.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -32.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +82.7% | +62.8% |
LFWD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LFWD and MBOT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| Market CapShares × price | $10M | $143M |
| Enterprise ValueMkt cap + debt − cash | $9M | $140M |
| Trailing P/EPrice ÷ TTM EPS | -0.38x | -2.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.45x | — |
| Price / BookPrice ÷ Book value/share | 8.99x | 9.44x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — LFWD and MBOT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MBOT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
MBOT delivers a -37.1% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-146 for LFWD. MBOT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to LFWD's 0.19x.
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| ROE (TTM)Return on equity | -145.5% | -37.1% |
| ROA (TTM)Return on assets | -78.4% | -34.4% |
| ROICReturn on invested capital | -122.9% | -6.2% |
| ROCEReturn on capital employed | -108.5% | -2.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.19x | 0.03x |
| Net DebtTotal debt minus cash | -$585,000 | -$3M |
| Cash & Equiv.Liquid assets | $2M | $3M |
| Total DebtShort + long-term debt | $2M | $111,000 |
| Interest CoverageEBIT ÷ Interest expense | -41.85x | — |
MBOT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MBOT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBOT five years ago would be worth $3,034 today (with dividends reinvested), compared to $470 for LFWD. Over the past 12 months, MBOT leads with a -16.8% total return vs LFWD's -60.4%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs LFWD's -50.0% — a key indicator of consistent wealth creation.
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| YTD ReturnYear-to-date | -13.0% | +0.9% |
| 1-Year ReturnPast 12 months | -60.4% | -16.8% |
| 3-Year ReturnCumulative with dividends | -87.5% | +85.2% |
| 5-Year ReturnCumulative with dividends | -95.3% | -69.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.4% |
| CAGR (3Y)Annualised 3-year return | -50.0% | +22.8% |
MBOT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LFWD and MBOT each lead in 1 of 2 comparable metrics.
Risk & Volatility
LFWD is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than MBOT's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MBOT currently trades 45.6% from its 52-week high vs LFWD's 36.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.90x |
| 52-Week HighHighest price in past year | $17.76 | $4.67 |
| 52-Week LowLowest price in past year | $0.67 | $1.60 |
| % of 52W HighCurrent price vs 52-week peak | +36.7% | +45.6% |
| RSI (14)Momentum oscillator 0–100 | 45.3 | 43.0 |
| Avg Volume (50D)Average daily shares traded | 11K | 1.5M |
Evenly matched — LFWD and MBOT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LFWD as "Buy" and MBOT as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 65.1% for LFWD (target: $11).
| Metric | LFWDLifeward Ltd. | MBOTMicrobot Medical … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.75 | $5.50 |
| # AnalystsCovering analysts | 5 | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MBOT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). LFWD leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMicrobot Medical Inc. (MBOT)Leads 2 of 6 categories
Loading custom metrics...
LFWD vs MBOT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LFWD or MBOT a better buy right now?
Analysts rate Lifeward Ltd.
(LFWD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LFWD or MBOT?
Over the past 5 years, Microbot Medical Inc.
(MBOT) delivered a total return of -69. 7%, compared to -95. 3% for Lifeward Ltd. (LFWD). Over 10 years, the gap is even starker: MBOT returned -99. 4% versus LFWD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LFWD or MBOT?
By beta (market sensitivity over 5 years), Lifeward Ltd.
(LFWD) is the lower-risk stock at 1. 22β versus Microbot Medical Inc. 's 1. 90β — meaning MBOT is approximately 56% more volatile than LFWD relative to the S&P 500. On balance sheet safety, Microbot Medical Inc. (MBOT) carries a lower debt/equity ratio of 3% versus 19% for Lifeward Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — LFWD or MBOT?
On earnings-per-share growth, the picture is similar: Lifeward Ltd.
grew EPS 57. 1% year-over-year, compared to 30. 5% for Microbot Medical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LFWD or MBOT?
Microbot Medical Inc.
(MBOT) is the more profitable company, earning 0. 0% net margin versus -90. 4% for Lifeward Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBOT leads at 0. 0% versus -76. 7% for LFWD. At the gross margin level — before operating expenses — LFWD leads at 38. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LFWD or MBOT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LFWD or MBOT better for a retirement portfolio?
For long-horizon retirement investors, Lifeward Ltd.
(LFWD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFWD: -100. 0%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LFWD and MBOT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.